Abbott Laboratories (NYSE:ABT) Stock Rating Upgraded by Wall Street Zen

by · The Markets Daily

Abbott Laboratories (NYSE:ABT – Get Free Report) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

ABT has been the topic of several other reports. UBS Group cut their price objective on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a research report on Tuesday, July 28th. Wolfe Research upgraded shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price objective for the company in a research note on Thursday, August 13th. Royal Bank Of Canada decreased their target price on shares of Abbott Laboratories from $130.00 to $125.00 and set an “outperform” rating for the company in a report on Thursday. Piper Sandler reiterated an “overweight” rating and issued a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. Finally, Rothschild & Co Redburn upgraded shares of Abbott Laboratories from a “neutral” rating to a “buy” rating and increased their price target for the company from $119.00 to $127.00 in a report on Friday, October 2nd. Two analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $118.32.

Read Our Latest Report on ABT

Abbott Laboratories Stock Performance

Shares of ABT opened at $103.70 on Friday. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The business’s 50 day moving average price is $105.15 and its 200-day moving average price is $98.29. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $132.02. The stock has a market cap of $179.45 billion, a P/E ratio of 38.70, a P/E/G ratio of 1.82 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.42. Abbott Laboratories had a return on equity of 17.97% and a net margin of 9.75%. The company had revenue of $13.01 billion during the quarter, compared to analyst estimates of $12.99 billion. During the same quarter last year, the company earned $1.30 EPS. The firm’s revenue for the quarter was up 14.5% on a year-over-year basis. Equities research analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Abbott Laboratories

Institutional investors have recently modified their holdings of the business. Manning & Napier Advisors LLC bought a new position in Abbott Laboratories during the 2nd quarter valued at about $31,000. Summit Securities Group LLC boosted its holdings in shares of Abbott Laboratories by 41.3% during the 2nd quarter. Summit Securities Group LLC now owns 404 shares of the healthcare product maker’s stock valued at $37,000 after acquiring an additional 118 shares during the last quarter. Addison Advisors LLC bought a new stake in shares of Abbott Laboratories in the second quarter worth approximately $40,000. Hoey Investments Inc. grew its stake in shares of Abbott Laboratories by 59.3% in the first quarter. Hoey Investments Inc. now owns 446 shares of the healthcare product maker’s stock worth $46,000 after acquiring an additional 166 shares during the period. Finally, E Fund Management Hong Kong Co. Ltd. grew its stake in shares of Abbott Laboratories by 221.6% in the second quarter. E Fund Management Hong Kong Co. Ltd. now owns 476 shares of the healthcare product maker’s stock worth $43,000 after acquiring an additional 328 shares during the period. 75.18% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

  • Positive Sentiment: New data presented at the European Society for Medical Oncology showed Abbott’s whole-genome sequencing Oncodetect® test delivered a 30% absolute improvement in sensitivity for detecting colorectal-cancer recurrence within two years of surgery. Patients with detectable molecular residual disease also faced a 10.6-fold higher recurrence risk, supporting the test’s clinical value and Abbott’s broader cancer-care strategy. Abbott Oncodetect ESMO data
  • Positive Sentiment: Wells Fargo upgraded its stance to “overweight” and raised its price target to $119, while other analysts retained buy or outperform ratings. These targets imply substantial potential upside and suggest Wall Street views the recent pullback as excessive. Wells Fargo rating
  • Neutral Sentiment: Abbott’s pacemaker and molecular-diagnostics markets are projected to grow, providing long-term demand opportunities. However, the reports also identify procedure costs, regulatory hurdles, cybersecurity risks and changing disease prevalence as industry constraints. Pacemaker market forecast
  • Negative Sentiment: Investors remain concerned about Abbott’s lowered 2026 sales-growth outlook. Management cited diabetes-related pricing pressure and weakness in the electrophysiology portfolio, issues that overshadowed a third-quarter earnings and revenue performance that broadly met expectations. Abbott 2026 guidance
  • Negative Sentiment: Abbott plans to spin off its approximately $8.5 billion Nutrition business by 2027. Although the transaction could sharpen the company’s focus and unlock value, investors face near-term uncertainty over separation costs, portfolio mix and the growth profile of the remaining business. Abbott Nutrition spin-off
  • Negative Sentiment: A comparative study claimed Catheter Precision’s LockeT device outperformed Abbott’s Perclose vascular-closure system. The potential competitive risk appears limited without evidence of meaningful revenue impact, but it adds pressure to Abbott’s medical-device franchise. LockeT and Perclose study

Abbott Laboratories Company Profile

(Get Free Report)

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.

Further Reading